{
    "ticker": "NPCE",
    "name": "NeuroPace, Inc.",
    "description": "NeuroPace, Inc. is a pioneering medical technology company focused on transforming the treatment of neurological disorders through innovative neurostimulation therapies. Founded in 2005, NeuroPace is best known for its flagship product, the RNS System, which is designed to treat refractory epilepsy. The RNS System is an implantable device that monitors brain activity and delivers targeted electrical stimulation to prevent seizures before they occur. This breakthrough technology represents a significant advancement in the management of epilepsy, offering patients a personalized approach to treatment that can improve their quality of life. NeuroPace is committed to advancing the field of neuromodulation and is actively engaged in research and development to expand its portfolio of therapies for other neurological conditions, such as depression and chronic pain. With a focus on patient-centric solutions, NeuroPace collaborates with healthcare providers and researchers to ensure its technologies meet the evolving needs of patients and clinicians alike. The company's vision is to unlock the potential of neurostimulation to provide relief for individuals suffering from debilitating neurological disorders, ultimately aiming to enhance patient outcomes and promote better health.",
    "industry": [
        "Medical Devices",
        "Neurotechnology"
    ],
    "headquarters": "Mountain View, California, USA",
    "founded": "2005",
    "website": "https://www.neuropace.com",
    "ceo": "Frank Fischer",
    "social_media": {
        "twitter": "https://twitter.com/NeuroPace",
        "linkedin": "https://www.linkedin.com/company/neuropace/"
    },
    "investor_relations": "https://investors.neuropace.com",
    "key_executives": [
        {
            "name": "Frank Fischer",
            "position": "CEO"
        },
        {
            "name": "Mark W. G. F. C. Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Neuromodulation Devices",
            "products": [
                "RNS System"
            ]
        }
    ],
    "seo": {
        "meta_title": "NeuroPace, Inc. | Innovating Neuromodulation for Epilepsy",
        "meta_description": "Explore NeuroPace, Inc., a leader in neurotechnology focused on advanced treatment options for neurological disorders like epilepsy through innovative neuromodulation therapies.",
        "keywords": [
            "NeuroPace",
            "Epilepsy Treatment",
            "Neuromodulation",
            "Medical Devices",
            "RNS System"
        ]
    },
    "faq": [
        {
            "question": "What is NeuroPace known for?",
            "answer": "NeuroPace is known for its innovative RNS System, which treats refractory epilepsy using neuromodulation technology."
        },
        {
            "question": "Who is the CEO of NeuroPace?",
            "answer": "Frank Fischer is the CEO of NeuroPace, Inc."
        },
        {
            "question": "Where is NeuroPace headquartered?",
            "answer": "NeuroPace is headquartered in Mountain View, California, USA."
        },
        {
            "question": "What is the main product of NeuroPace?",
            "answer": "NeuroPace's main product is the RNS System, an implantable device for managing epilepsy."
        },
        {
            "question": "When was NeuroPace founded?",
            "answer": "NeuroPace was founded in 2005."
        }
    ],
    "competitors": [
        "ZTS",
        "MDT",
        "BSX"
    ],
    "related_stocks": [
        "ABBV",
        "JNJ",
        "PFE",
        "VRTX"
    ]
}